CD19 and neoplasm: At baseline, significant differences were observed in the percentages of CD3 + CD8 + T cells, CD16 + CD56 + NK cells, CD19 + B cells and the absolute counts of CD19 + B cells between the TRG0 (marked tumor regression) and non-TRG0 (TRG1-3, mild or no regression) groups (Supplementary Fig. 1).